Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis
Guselkumab probably leads to higher proportion of participants achieving a 50% reduction in disease… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants cleared or almost cleared ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
Secukinumab probably leads to higher proportion of participants with adverse effects serious or severe… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis
Topical vitamin D derivative may leads to higher proportion of participants cleared or almost cleared in the short… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis
Secukinumab probably leads to higher proportion of participants with a 50% reduction in disease severity compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects in the short term ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · chronic pruritus of unknown origin
Serlopitant 5 mg may leads to higher patient‐reported pruritus intensity compared with placebo (low certainty).
1 finding from 1 review
Sleep disturbances: number of participants with insomnia · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).
1 finding from 1 review
Depression · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · chronic pruritus of unknown origin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pruritus · chronic pruritus of unknown origin
Serlopitant 0.25 mg showed no clear difference in patient‐reported pruritus intensity compared with placebo (low certainty).
1 finding from 1 review
Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · chronic pruritus of unknown origin
1 finding from 1 review